Autolus Therapeutics plc (AUTL): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2021-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$262.25M

Year ended 2025-12-31

-$238.85M

Trailing 12 months to 2026-06-30

2019-12-31 EBITDA (USD) 2025-12-31

Period ended	EBITDA	Change YoY	Source filing
2025-12-31	-$262.25M	n/m	2026-03-27, From 2025-01-01
2024-12-31	-$233.87M	n/m	2026-03-27, From 2024-01-01
2023-12-31	-$173.14M	n/m	2025-03-20, From 2023-01-01
2022-12-31	-$135.99M	n/m	2024-03-21, From 2022-01-01
2021-12-31	-$132.59M	n/c	2024-03-21, From 2021-01-01
2020-12-31	-$162.49M	n/m	2023-03-07, From 2020-01-01
2019-12-31	-$141.45M	n/a	2022-03-10, From 2019-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	EBITDA	Change YoY
Autolus Therapeutics plc (AUTL)	2025-12-31	-$262.25M	n/m
Recursion Pharmaceuticals, Inc. (RXRX)	2025-12-31	-$564.43M	n/m
MeiraGTx Holdings plc (MGTX)	2025-12-31	-$93.43M	n/m
Vir Biotechnology, Inc. (VIR)	2025-12-31	-$467.65M	n/m
4D Molecular Therapeutics, Inc. (FDMT)	2025-12-31	-$154.85M	n/m
Champions Oncology, Inc. (CSBR)	2026-04-30	$237.0K	-96.2%
Sutro Biopharma, Inc. (STRO)	2025-12-31	-$151.04M	n/m
ImmunityBio, Inc. (IBRX)	2025-12-31	-$240.50M	n/m
Agenus Inc (AGEN)	2025-12-31	-$10.17M	n/m

Compare AUTL, RXRX, MGTX, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗